ArticleBJC reports2026
A comprehensive genomic framework for identifying genes predisposing to homologous recombination repair-deficient breast or ovarian cancer.
Article in BJC reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPatients with clinical characteristics of increased cancer susceptibility without an identified genetic lesion are regularly seen in clinics. Association studies and matched normal/tumour sequencing have advanced the discovery of Cancer Susceptibility Genes (CSGs), with limitations when used independently. We reasoned that combining these strategies alongside mutational signatures and clinical data could improve CSGs identification.
methodsUsing breast and ovarian cancer exome data from The Cancer Genome Atlas (TCGA-BRCA and TCGA-OV), we developed a genomic framework that evaluates exome-wide associations of Germline Pathogenic Variants (GPVs) harbouring second hits with Homologous Recombination Repair Deficiency (HRD) mutational signatures (HRDSig) to identify novel HRD-related CSGs. This is complemented by clinico-genomic analysis evaluating clinical and biological plausibility.
resultsOur framework confirmed significant associations with HRDSig of BRCA1/2 GPVs with second hits in both TCGA cohorts, validating its performance. THBS4 also reached significance but only co-occurred with other HRD-related events in TCGA-BRCA. Borderline significance was also observed for KIF13B and TESPA1, also only in TCGA-BRCA. The clinico-genomics approach further identified KIF13B and TESPA1, as well as RAD51B and other Fanconi Anaemia pathway-related genes, including FANCD2, warranting further validation.
conclusionsOur approach provides a framework for the identification of candidate HRD-related CSGs through combined statistical and clinico-genomics analyses. It is adaptable to other mutational signatures/cancer types and will be most effective when applied to larger and well-annotated datasets.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.